Drug
IBI-10090
IBI-10090 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
200%(4 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_2
3
75%
Ph phase_3
1
25%
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Completed2
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 3
Trials by Phase
Phase 23 (75.0%)
Phase 31 (25.0%)
Trials by Status
completed250%
terminated250%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery
NCT01048593
completedphase_3
The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
NCT02006888
completedphase_2
Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
NCT01606735
terminatedphase_2
Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients
NCT01214174
Clinical Trials (4)
Showing 4 of 4 trials
NCT01048593Phase 2
Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery
NCT02006888Phase 3
The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
NCT01606735Phase 2
Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
NCT01214174Phase 2
Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4